6th Annual Next-Gen Immuno-Oncology Conference: Focus on Combination Strategies, Pre-clinical and Translational Immune-oncology Developments (Boston, United States - June 22-23, 2023) - ResearchAndMarkets.com
23 May 2023
ImmunotherapyAACRCell Therapy
DUBLIN--(BUSINESS WIRE)--The "6th Annual Next-Gen Immuno-Oncology Conference" has been added to ResearchAndMarkets.com's offering.
The 6th Annual Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, in Boston, would address the challenges and future directions in IO research.
The congress aims to bring academicians, researchers, and scientists from research institutes pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC's, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors.
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development, and personalized immunotherapy.
Keynote presentations, Brainstorming Panel Discussions, and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma, and biotech companies, the congress will discuss the latest updates in the development of ADC's, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy
Key Highlights
Updates in development of ADC's and Bispecific Ab's
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses
Why attend?
Exclusive conference to learn about antibodies, cellular therapy, and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session
Who Should Attend:
CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on
Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors
Agenda:
DAY ONE
08:15 - 08:50 Registration
08:50 - 08:55 Welcome note
08:55 - 09:00 Opening remarks from the Chairman - New Antibody Formats & Cellular Therapy
09:00 - 09:30 Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics
09:30 - 10:00 Solution Provider Presentation
10:00 - 10:30 Precision Medicine in IO-Case study
10:30 - 11:15 Morning Refreshments and Poster Presentations | One-to-One Networking Meetings
11:15 - 11:45 Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers Rakesh Dixit, CEO, Bionavigen
11:45 - 12:15 Adoptive Cellular Therapy
12:15 - 12:45 Targeting cancer with ADC's-Case study
12:45 - 13:15 Development of bispecific antibodies for cancer therapy
13:15 - 14:15 Lunch and Poster Presentations | One-to-One Networking Meetings
14:15 - 14:45 Challenges in the nonclinical development of mAb-based cancer immunotherapy
14:45 - 15:15 Dendritic cell therapy in IO
15:15 - 15:45 Solution Provider Presentation
15:45 - 16:30 Afternoon Refreshments and Poster Presentations | One-to-One Networking Meetings
16:30 - 17:00 Preclinical safety/toxicity evaluation of next generation CAR-T/TCR-T therapies Yixiang Xu, Senior Scientist, Bristol Meyers Squibb
17:00 - 17:30 Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736) Nadia Hassounah, Principal Scientist, Novartis
17:30 - 18:00 Choosing IO in multiple myeloma-Case Study
18:00 - 18:00 Closing remarks from the Chairman
18:00 - 18:00 End of Day 1 followed by Drinks Reception and Networking
DAY 2
08:15 - 08:50 Registration
08:50 - 08:55 Welcome note
08:55 - 09:00 Opening remarks from the Chairman - New Immune Checkpoints, Biomarker and Tumour Microenvironment
09:00 - 09:30 Keynote
09:30 - 10:00 Solution Provider Presentation
10:00 - 10:30 Role of Tumour Micro-Enviroment in Oncolytic Viral Therapy
10:30 - 11:15 Morning Refreshments and Poster Presentations | One-to-One Networking Meetings
11:15 - 11:45 Solution Provider Presentation
11:45 - 12:15 New IO Combination therapies and Biomarkers
12:45 - 13:15 Cancer Vaccines and new developments
13:15 - 14:15 Lunch and Poster Presentations | One-to-One Networking Meetings
14:15 - 14:45 Combining oncolytic viruses with immune checkpoint inhibitors
14:45 - 15:15 Solution Provider Presentation
15:15 - 15:45 Immunomodulation in IO
15:45 - 15:45 Closing remarks from the Chairman
End of Conference
For more information about this conference visit https://www.researchandmarkets.com/r/hqt0a1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.